Low-Dose immunotherapy shows promise against tough colorectal cancer
NCT ID NCT07523763
First seen May 02, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This study tests a low-dose immunotherapy (nivolumab or pembrolizumab) in 30 people with a specific type of advanced colorectal cancer (MSI/dMMR). The goal is to see if 6 months of treatment can make the tumor disappear or shrink enough to avoid surgery. Participants have stage II-III cancer and are followed for up to 6 months to check for complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia
Conditions
Explore the condition pages connected to this study.